Investigational drug · Phase 3
VLA1553
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chikungunya Virus Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "VLA1553"
First trial start
2021
Apr 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VLA1553", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chikungunya Virus Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VLA1553" as an intervention, largest first.
- Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruiting
Valneva Austria GmbHIndustry
NCT07163845 · 5,354 participants · Start Sep 22, 2025 · Primary completion Jul 31, 2026
Drug: Live-attenuated CHIKV vaccine VLA1553 · For: Chikungunya Virus Infection
Sites: Fortaleza, Brazil; Belo Horizonte, Brazil; Laranjeiras, Brazil · 4 sites in all
- Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruiting
Valneva Austria GmbHIndustry
NCT07254702 · 5,000 participants (planned) · Start Feb 2, 2026 · Primary completion Oct 31, 2026
Drug: Live-attenuated CHIKV vaccine VLA1553 · For: Chikungunya Virus Infection
Sites: Belo Horizonte, Brazil; Laranjeiras, Brazil; São Pedro, Brazil
- Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in AdultsPivotal-lookingCompleted
Valneva Austria GmbHIndustry
NCT04546724 · 4,128 participants · Start Sep 17, 2020 · Primary completion May 19, 2021
Drug: VLA1553; Placebo · For: Chikungunya Virus Infection
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 44 sites in all
- Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilEnrolling by invitation
Valneva Austria GmbHIndustry
NCT07347002 · 1,200 participants (planned) · Start Feb 2, 2026 · Primary completion Dec 31, 2027
Drug: Live-attenuated CHIKV vaccine VLA1553 · For: Chikungunya Virus Infection
Sites: Belo Horizonte, Brazil; Laranjeiras, Brazil; São Pedro, Brazil
- A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in AdolescentsPivotal-lookingCompleted
Butantan InstituteGovernment (non-federal)
NCT04650399 · 754 participants · Start Feb 14, 2022 · Primary completion Mar 14, 2023
Drug: Active; Placebo · For: Chikungunya
Sites: Boa Vista, Brazil; Manaus, Brazil; Fortaleza, Brazil · 10 sites in all
- Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy AdultsPivotal-lookingCompleted
Valneva Austria GmbHIndustry
NCT04786444 · 409 participants · Start Feb 22, 2021 · Primary completion Jul 22, 2021
Drug: Biological Vaccine VLA1553 · For: Chikungunya Virus Infection
Sites: Coral Gables, Florida; Fort Myers, Florida; Ponte Vedra, Florida · 12 sites in all
- Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)Pivotal-lookingActive, not recruiting
Valneva Austria GmbHIndustry
NCT04838444 · 363 participants · Start Apr 2, 2021 · Primary completion Mar 3, 2023
Drug: VLA1553 · For: Chikungunya Virus Infection
Sites: Phoenix, Arizona; Hallandale, Florida; Chicago, Illinois · 10 sites in all
- A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsPivotal-lookingCompleted
Valneva Austria GmbHIndustry
NCT06106581 · 304 participants · Start Dec 18, 2023 · Primary completion Jul 31, 2024
Drug: VLA1553 full dose; VLA1553 half dose and 1 more · For: Chikungunya Virus Infection
Sites: Santo Domingo, Dominican Republic; Tegucigalpa, Honduras · 3 sites in all
- VLA1553-403 Pregnancy Surveillance StudyEnrolling by invitation
Valneva Austria GmbHIndustry
NCT07414524 · 200 participants (planned) · Start Jun 11, 2026 · Primary completion Dec 31, 2027
Drug: Live-attenuated CHIKV vaccine VLA1553; Vaccine(s) approved for use during pregnancy by the MoH · For: Chikungunya Virus Infection
Sites: Belo Horizonte, Brazil; Laranjeiras, Brazil; São Pedro, Brazil
- Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy VolunteersPivotal-lookingCompleted
Valneva Austria GmbHIndustry
NCT03382964 · 120 participants · Start Mar 5, 2018 · Primary completion Jul 13, 2018
Drug: VLA1553 · For: Chikungunya
Sites: Huntsville, Alabama; Peoria, Illinois
Newest research
PubMed records naming it or its code names, newest first.
- Rapid differentiation of VLA1553 and wild-type ECSA chikungunya strains in the context of an IXCHIQ vaccination campaign.
Pezzi L, Frumence E, Wesselmann K, et al. · Emerg Microbes Infect 2026
- Study protocol for a retrospective cohort study of real-world effectiveness of the VLA1553 (IXCHIQ®) chikungunya vaccine during an epidemic among healthcare workers in Reunion Island.
Mosnier E, Benhard J, Badia V, et al. · Infect Dis Now 2026
- Dengue and chikungunya vaccines past, present and future: implications for travelers.
Norman FF, McGuinness SL, Chen LH · Curr Opin Infect Dis 2026
- A nanoluciferase-expressing attenuated CHIKV vaccine strain enables rapid and visual drug screening in vitro and in vivo.
Zheng M, Pan Z, Jiang Y, et al. · J Virol 2026
- Chikungunya fever-What we know and have done in the face of a new global public health threat.
Yu XL, Zhou RY, Xie XY, et al. · J Integr Med 2026
- Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®).
Sattler N, Scheiblauer S, Hochreiter R, et al. · Vaccine 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.